CTNNA2 and neoplasm: Our results not only confirm the role of CTNNA2 mutation in LUAD but also suggest that the effect of CTNNA2 may occur via changes to the immune microenvironment, providing strong evidence for CTNNA2 as a new tumor microenvironment therapeutic target.